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A B S T R A C T
Purpose
This is the first study in which the NK1-receptor antagonist, aprepitant (APR), was evaluated
for the prevention of chemotherapy-induced nausea and vomiting (CINV) with moderately
emetogenic chemotherapy.
Patients and Methods
Eligible breast cancer patients were naive to emetogenic chemotherapy and treated with
cyclophosphamide doxorubicin or epirubicin. Patients were randomly assigned to either an
aprepitant regimen (day 1, APR 125 mg, ondansetron (OND) 8 mg, and dexamethasone 12
mg before chemotherapy and OND 8 mg 8 hours later; days 2 through 3, APR 80 qd) or a
control regimen (day 1, OND 8 mg and dexamethasone 20 mg before chemotherapy and
OND 8 mg 8 hours later; days 2 through 3, OND 8 mg bid). Data on nausea, vomiting, and
use of rescue medication were collected with a self-report diary. The primary efficacy end
point was the proportion of patients with complete response, defined as no vomiting and no
use of rescue therapy, during 120 hours after initiation of chemotherapy in cycle 1. The
secondary end point was the proportion of patients with an average item score higher than
6 of 7 on the Functional Living Index–Emesis questionnaire.
Results
Of 866 patients randomized, 857 patients (99%) were assessable. Overall complete
response was greater with the aprepitant regimen than with the control regimen (50.8% v
42.5%; P  .015). More patients in the aprepitant group reported minimal or no impact of
CINV on daily life (63.5% v 55.6%; P .019). Both treatments were generally well tolerated.
Conclusion
The aprepitant regimen was more effective than the control regimen for prevention of CINV
in patients receiving both an anthracycline and cyclophosphamide.
J Clin Oncol 23:2822-2830. © 2005 by American Society of Clinical Oncology
INTRODUCTION
Despite the use of a 5-HT3–receptor antag-
onist and dexamethasone in accordance
with evidence-based consensus guidelines,
many cancer patients still experience
chemotherapy-induced nausea and vomit-
ing (CINV). Although cisplatin is recog-
nized as being particularly emetogenic,
numerous other chemotherapeutic agents
are also emetogenic, particularly when ad-
ministered in combination regimens. A va-
riety of classification schemes defining
emetogenicity of individual chemothera-
peutic agents have been published in which
a cisplatin dose of more than 50 mg/m2 is
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consistently defined as being highly emetogenic, and agents
such as cyclophosphamide, doxorubicin, and epirubicin are
generally defined as being moderately emetogenic.1,2
Recommended antiemetic therapy for moderately
emetogenic chemotherapy (MEC) consists of a corticoste-
roid plus a 5-HT3–receptor antagonist before chemother-
apy, followed by a 5-HT3–receptor antagonist and/or a
corticosteroid on subsequent days.2,3 Many physicians are
reluctant to prescribe corticosteroids on multiple days, and
so the most common approach is to use a 5-HT3–receptor
antagonist on multiple days.4 It is notable that recent stud-
ies describe an incidence of CINV of approximately 50% in
patients receiving MEC,5-8 including breast cancer patients
treated with 5-HT3–receptor antagonists.
9,10 Hence, there
is clearly a need for more effective prevention of CINV in
patients receiving MEC, especially in women, who are par-
ticularly susceptible to these symptoms.11
Several lines of evidence suggest that NK1-receptor
antagonists, such as aprepitant, might be useful antiemetics
in the prevention of CINV associated with emetogenic
noncisplatin-based chemotherapy and other regimens de-
fined as moderately emetogenic chemotherapy. Several
large studies have shown that addition of aprepitant to a
regimen including granisetron or ondansetron and dexa-
methasone improved the prevention of emesis throughout
the acute and delayed phases in patients receiving cisplatin-
based highly emetogenic chemotherapy (HEC).12-14 The
benefit of aprepitant appeared to be particularly pro-
nounced in patients receiving cisplatin with cyclophospha-
mide and/or doxorubicin.15 Antiemetic therapies that have
been shown to be effective in preventing CINV associated
with cisplatin, such as 5-HT3–receptor antagonists,
dopamine-receptor antagonists, and corticosteroids, have
consistently also been shown to be effective in preventing
CINV associated with other chemotherapy agents. Finally,
preclinical studies had previously shown that another NK1-
receptor antagonist, GR203040, prevented emesis in ferrets
treated with cyclophosphamide.16
This study of aprepitant in breast cancer patients
treated with cyclophosphamide-based chemotherapy was
designed to clarify the potential role of an NK1-receptor
antagonist in patients receiving MEC. The study compared
the efficacy and tolerability of an aprepitant regimen with
an active control regimen in preventing CINV in a patient
population that is known to be very susceptible to CINV.
The primary hypothesis was that the aprepitant regimen
would be superior to the control regimen, as measured by
the proportion of patients with complete response, which
was defined as no vomiting and no rescue therapy, through-
out the acute and delayed phases (120 hours) after the first
cycle of chemotherapy, and that both regimens would be
well tolerated. The secondary hypothesis was that the
aprepitant regimen would be superior to the control regi-
men in the proportion of patients with minimal or no
impact of emesis on daily living, as measured using the
Functional Living Index–Emesis (FLIE) questionnaire.
PATIENTS AND METHODS
Inclusion Criteria
Patients were included in the study if they had breast cancer
that was being treated withmoderately emetogenic chemotherapy
that included intravenous cyclophosphamide. Institutional review
boards at each study site approved the study protocol, and written
informed consent was obtained from all participants before en-
rollment. Patients were at least 18 years old and had to be naive to
emetogenic chemotherapy (Hesketh Level 3 or higher1), and
scheduled to receive their first course of MEC. The following
agents were administered either alone or in combination: intrave-
nous (IV) cyclophosphamide 750 to 1,500 mg/m2 ( 5%); IV
cyclophosphamide 500 to 1,500 mg/m2 ( 5%) and IV doxorubi-
cin  60 mg/m2 ( 5%); IV cyclophosphamide 500 to 1,500
mg/m2 ( 5%) and IV epirubicin  100 mg/m2 ( 5%); other
chemotherapeutic agentsHesketh Level 2 or lowerwere allowed to
be added to the above chemotherapeutic regimens. Patients had to
have a predicted life expectancy of  4 months and a Karnofsky
score of 60 to be eligible for the study.
Exclusion Criteria
Patients were excluded if they had a symptomatic CNS ma-
lignancy; received radiation therapy to the abdomen or pelvis in
the week before treatment; had vomited in the 24 hours before
treatment day 1; had an active infection, an active systemic fungal
infection, or any severe concurrent illness except for malignancy;
or had abnormal laboratory values (including absolute neutrophil
count  1,500/mm3, WBC count  3,000/mm3, platelet count
 100,000/mm3, AST  2.5 the upper limit of normal, ALT
 2.5 the upper limit of normal, bilirubin  1.5 the upper
limit of normal, creatinine  1.5 the upper limit of normal).
Patients taking systemic corticosteroid therapy at any dose were
excluded. Antiemetic agents could not be administered within 48
hours before treatment, except for single daily doses of lorazepam.
Study Design
This was a prospective, double-blind, double-dummy,
parallel-group study conducted at 95 centers in the United States,
Germany, Austria, Canada, Hong Kong, Hungary, Spain, United
Kingdom, Italy, Australia, and Greece. Patients in each treatment
group were instructed to take a daily dose of the study drug for the
3-day period, according to the treatment regimens listed in Table
1. The value of 5-HT3–receptor antagonists during the acute phase
is well recognized, so ondansetron was included in both treatment
groups on day 1. Because the value of 5-HT3–receptor antagonists
in the delayed phase is of uncertain benefit, themost parsimonious
approach was taken when deciding treatment during this period,
whichwas to eliminate the ondansetron and replace it with aprepi-
tant. To ensure similar dexamethasone plasma exposure between
treatment groups, the dexamethasone dose in the aprepitant reg-
imen was reduced by 40%, based on a pharmacokinetic study that
showed that aprepitant increased dexamethasone levels by ap-
proximately two-fold.17 On days 4 and 5, measurements were
taken, but no treatmentwas given. Patients kept a diary tomonitor
efficacy from the initiation of chemotherapy infusion (0 hours)
until the morning of day 6 ( 120 hours) after chemotherapy
infusion. The diary documented the date and time of any emetic
Aprepitant for CINV Due to MEC
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episodes and use of rescue medication, as well as daily nausea
ratings (by visual analog scale [VAS]; 0 mm is “no nausea,” 100
mm is “nausea as bad as it could be.”) Patients were allowed to take
rescue therapy throughout the study for nausea or vomiting as
needed; permitted rescue medications were: 5-HT3–antagonists,
phenothiazines, butyrophenones, benzodiazepines, benzamides,
corticosteroids, and domperidone. The results presented here are
for cycle 1 only; results for additional cycles will be the subject of a
future article. Note that the data for cycle 1 was not unblinded for
analysis until all patients randomly assigned to the study had
completed the study.
Patient-Reported Impact on Daily Life
The FLIE questionnaire is a validated patient-reported mea-
sure of the impact of CINV on daily life.18 It is a short, self-
administered instrument containing two domains—one for
nausea (9 items) and one for vomiting (9 items). The FLIE ques-
tionnaire was administered before the initiation of chemotherapy
infusion on day 1, and on day 6, immediately after completion of
the diary. Responses to each question are rated on a 100-mmVAS
that was scored on a 1- to 7-point scale as described in the FLIE
Scoring Manual. For this study, “minimal or no impact of CINV
on daily life” is defined as an average score of more than 6 on the
7-point scale (ie,  108 total score [nausea domain score 
vomiting domain score] or 54 domain score).
Statistical Methods
Patients who met eligibility criteria were randomly assigned
to either the aprepitant regimen or the control regimen using a
computer-generated allocation schedule with a block size of four.
With a sample size of 375 assessable patients per regimen, and
assuming a response ratewith the control regimen of 52% (data on
file, Merck & Co Inc pilot study), this study would have approxi-
mately 80% power to detect the superiority of the aprepitant
regimen, if the true aprepitant regimen effect is 10 percentage
points higher than the control regimen. A type I error of 0.05 was
used in the determination of sample size.
Surveillance of the emerging study data was carried out by an
independent group, the Data Safety and Monitoring Board
(DSMB). The DSMB were unblinded to study safety data as
deemed necessary to fulfill its charge of identifying safety issues
and assessing (and identifying) drug-related treatment-emergent
adverse events (AE) in order to make periodic recommendations
on protocol modifications, and on whether to continue or termi-
nate the study.
The primary efficacy hypothesis was that the aprepitant reg-
imen would be superior to the control regimen in the proportion
of patients with complete response, which was defined as no
vomiting with no use of rescue therapy, in the 120 hours after the
first cycle of chemotherapy. The primary safety hypothesis was
that the aprepitant regimen and the control regimenwould bewell
tolerated in the first cycle of chemotherapy. The secondary hy-
pothesis stated that the aprepitant regimen would be superior to
the control regimen in the proportion of patients with minimal or
no impact on daily life according to the FLIE questionnaire during
the first cycle of chemotherapy.
Amodified intention-to-treat (mITT) approach was used for
all efficacy analyses; a patient must have received chemotherapy,
been administered a dose of the study drug, and have at least one
post-treatment assessment on day 1 (required for acute phase) and
day 2 (required for both delayed phase and overall analyses) to be
included in the analysis. However, if a patient’s treatment was
identified as a “failure” in the overall or delayed phases, regardless
of the day in the phase, then that patient was included in themITT
analysis for that respective phase in cycle 1. The primary end point
used to evaluate efficacy was the proportion of patients reporting
complete response during the overall 0 to 120 hours after initiation
of MEC (cycle 1). Exploratory end points included complete re-
sponse in the acute and delayed time frames (0 to 24 and 24 to 120
hours, respectively), and the following in acute, delayed, and over-
all time frames: no emesis (no vomiting or retching), no use of
rescue therapy, no significant nausea (VAS  25 mm), and no
nausea (VAS 5mm). The time to first vomiting episode was also
assessed. For all binary outcome efficacy measures, comparison
between the aprepitant regimen and the control regimen was
made using a logistic regression model with factors for treatment
allocation, investigator group (grouped by region in the United
States, East versus Middle/West, and by country for non-
US groups, to avoid sparse data problems), and age category
( 55 years, 55 years). All tests of hypothesis used a two-sided
significance level of 5%. Interactions between treatment and in-
vestigator group, and treatment and age category ( 55 years,
 55 years) were assessed in a separate model using a significance
level of .10. For the time to first vomiting episode, Kaplan-Meier
curves depicting the percentage of patients who had no vomiting
Table 1. Study Medication Schedule
Regimen and Study Medication
Dose
Day 1 Day 2 Day 3
Aprepitant (n  438)
Aprepitant 125 mg po 1 hour before chemotherapy 80 mg po 80 mg po
Ondansetron 8 mg po 30 to 60 minutes before chemotherapy;
8 mg po 8 hours after first dose
Placebo po bid Placebo po bid
Dexamethasone 12 mg po 30 minutes before chemotherapy
Control (n  428)
Aprepitant Placebo po Placebo po Placebo po
Ondansetron 8 mg po 30 to 60 minutes before chemotherapy;
8 mg po 8 hours after first dose
8 mg po bid 8 mg po bid
Dexamethasone 20 mg po 30 minutes before chemotherapy
Abbreviation: po, orally.
Warr et al
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episodes since the initiation of chemotherapy were generated for
each of the treatment regimens. A log-rank test stratifying investi-
gator group and age category ( 55 years, 55 years) was used for
the treatment comparison.
For the analysis of the FLIE questionnaire, treatment groups
were compared with respect to the proportion of patients with a
total score of more than 108 (minimal or no impact) using a
logistic regression model. If the proportion of patients with min-
imal or no impact was statistically significantly different between
groups, then a separate evaluation would be carried out for each
domain (nausea, vomiting) score, and, if significant for a domain, for
three individual items for each domain (ability to enjoy a meal, daily
functioning, andpersonal hardship).Hochberg’s procedurewasused
as a multiplicity adjustment when testing individual items.19
All patients treated were included in the safety analyses.
Safety and tolerability were assessed by statistical and clinical
review of AEs, vital signs, and laboratory values. The primary
variable for the safety assessment was the incidence of overall AEs
occurring in cycle 1. Fisher’s exact test was used tomake treatment
comparisons with respect to the incidence of AEs.
The statistical analyses were completed by the study sponsor
with significant input from the study investigators.
Fig 1. Study flow chart. Patient disposition during the study. (†) Completed the day 14 to 29 visit. Chemo, chemotherapy.
Aprepitant for CINV Due to MEC
www.jco.org 2825
Downloaded from ascopubs.org by 147.8.230.123 on March 21, 2018 from 147.008.230.123
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
RESULTS
From October 2002 to December 2003, 866 patients from
95 centers around the world were randomly assigned to
either the aprepitant regimen or the control regimen. Pa-
tient accounting is shown in Figure 1. A fairly small percent-
age (5%) of potentially eligible patients did not enroll onto
the study. Nine patients (1%) were considered ineligible for
evaluation and were excluded from themodified intention-
to-treat analysis of the primary end point.
Patient characteristics and treatment regimens are
listed in Table 2. Treatment groups were similar with re-
spect to baseline characteristics. The majority of patients
were white (78.6%) and female (99.8%). Ninety-nine per-
cent of patients received a combination of cyclophospha-
mide plus an anthracycline as their chemotherapy regimen;
six patients received cyclophosphamide plus fluorouracil
plus methotreaxate.
Complete Response
The primary efficacy end point of overall complete
response is defined as no emetic episodes and no use of
rescue medication during the 5 days (120 hours) after initi-
ation of chemotherapy. Overall, significantly more patients
in the aprepitant group reported complete response than in
the control group (51% v 42%; P  .015, adjusted for
treatment group, investigator group, and age category; Fig
2). A sensitivity analysis was performed adjusting only for
treatment group, and showed similar results with P .014.
There was no evidence of treatment-by-subgroup inter-
actions, including race. More patients taking aprepitant
achieved a complete response during both acute (76% v
69%; P  .034) and delayed (55% v 49%; P  .064)
phases (Fig 3). Analysis of the components of complete
response, vomiting and using rescue medication, showed
that significantly more patients taking aprepitant re-
ported no vomiting (76% v 59%; P .001), but there was
no significant difference between groups in the use of
rescue therapy.
Impact on Daily Living
On the FLIE questionnaire, significantly more patients
taking the aprepitant regimen reported minimal or no im-
pact on daily living overall (Fig 4). There were significant
differences favoring aprepitant in the vomiting domain
score (85.7% v 71.8%; P  .001), as well as in individual
items, but not in the nausea domain score (53.5% v 50.5%).
Exploratory End Points
Figure 5 shows the Kaplan-Meier curve for the time to
first emesis after the initiation of chemotherapy. The supe-
riority of the aprepitant regimen versus the control regimen
Table 2. Patient Characteristics
Characteristics
% of Patients
Aprepitant Regimen
(n  438)
Control Regimen
(n  428)
Female 99.5 100
Age, years
Mean 53.1 52.1
SD 10.7 10.9
Race, white 79.7 77.6
History of motion sickness 16.9 21.0
History of vomiting during pregnancy 30.8 30.1
Primary diagnosis
Infiltrating ductal carcinoma 81.5 83.2
Infiltrating lobular carcinoma 8.7 7.0
Stage of malignancy
I 21.5 22.2
II 57.5 57.9
IIIa 11.6 11.0
IIIb 5.5 4.7
IV 3.4 3.3
Chemotherapy regimen
Cyclophosphamide  doxorubicin 61.0 60.3
Cyclophosphamide  doxorubicin  docetaxel 0.5 0.9
Cyclophosphamide  doxorubicin  fluorouracil 7.8 7.0
Cyclophosphamide  doxorubicin  paclitaxel 0.5 0
Cyclophosphamide  epirubicin 8.0 8.4
Cyclophosphamide  epirubicin  fluorouracil 20.8 22.4
Cyclophosphamide  fluorouracil  methotrexate 1.4 0.9
Abbreviation: SD, standard deviation.
Two patients were men.
Warr et al
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became apparent early, at approximately 6 hours, and the
gap between the treatments continued to widen over the
5-day period. There were no significant differences between
the two treatment groups in reports of overall nausea (VAS
 5 mm; 33% for both) or significant nausea (VAS  25
mm; aprepitant 61%, control 56%).
Tolerability
The DSMBmet several times throughout the course of
the study to review summaries of the safety data; no issues
were detected. The percentage of patients with clinical AEs
or laboratory abnormalities during the study is listed in
Table 3. The only appreciable difference in tolerability was a
slightly higher rate of constipation in the control group
(18.0% v 12.3%) and slightly more dyspepsia in the aprepi-
tant group (8.4% v 4.9%). The incidence of investigator-
reported febrile neutropenia was identical for both
treatments (2.1%).
DISCUSSION
This large clinical trial in women with breast cancer ad-
dressed the potential utility of an NK1-receptor antagonist
as a component of a regimen with a corticosteroid and a
5-HT3–receptor antagonist for the prevention of CINV in-
duced by cyclophosphamide-based chemotherapy. As seen
in previous trials with cisplatin-based HEC,12-14,20 addition
of aprepitant to an antiemetic regimen containing a 5-HT3–
receptor antagonist, ondansetron, and a corticosteroid,
dexamethasone, was superior to ondansetron and dexa-
methasone alone in the proportion of patients achieving a
complete response overall after one cycle of MEC. This
study is notable for MEC antiemetic studies in terms of the
homogeneity of the patient population and also the unifor-
mity of the emetogenic stimulus provided. Although the
chemotherapy regimen that patients received in this study is
defined as moderately emetogenic, the relatively low com-
plete response rate of 42% in the control group clearly
underscores the need for improved therapy in this patient
Fig 3. Graph showing percentage of pa-
tients with complete response (CR; no vom-
iting and no use of rescue therapy) from 0-24
hours (acute) and 24-120 hours (delayed)
after initiation of the first cycle of chemother-
apy. (†) P values are for between-group
differences (for summary purposes only).
Black bars aprepitant; gray bars control.
Fig 2. Complete response (CR) and components. Bar graph showing the
percentage of patients with a CR, defined as no vomiting and no use of
rescue therapy, during the 120 hours after the initiation of the first cycle of
chemotherapy. P values are for between-group differences. Black bars 
aprepitant regimen; gray bars  control regimen. NS, not significant.
Aprepitant for CINV Due to MEC
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population. The choice of comparator regimen, ondanse-
tron bid and dexamethasone on day 1 followed by ondan-
setron bid on days 2 and 3, was much more rigorous than
the regimens in recently published MEC antiemetic stud-
ies21,22 in which the control arm treatment regimen con-
sisted of only a single dose of a 5-HT3–receptor antagonist;
hence, this study is particularly relevant to clinical practice.
Aprepitant clearly provided significant benefit (eight
percentage points during 120 hours; P .015) throughout
the acute and delayed phases. That the response was not as
pronounced as that seen with the addition of aprepitant in
patients receiving cisplatin-based chemotherapy is proba-
bly a consequence of the potency of the emetogenic stimu-
lus of the combination of cyclophosphamide and an
anthracycline in women, who are known to be more sus-
ceptible to CINV. It is also worth noting that the control
therapy group was administered a 5-HT3–receptor antago-
nist beyond day 1, whereas the experimental aprepitant
group did not, and there is evidence that administering
5-HT3–receptor antagonists beyond 24hours can enhance the
control of delayed-phase symptoms associated withMEC.8,23
The aprepitant effect was more pronounced early ( 6
hours) in the acute phase in this study, whereas the aprepi-
tant effect was more notable later ( 18 hours) in the
cisplatin HEC studies.12-14,20 This may be a consequence of
the mechanism of CINV caused by the chemotherapy used
in the present study, or of the patient population (almost
exclusively women). Importantly, though, the benefit is
clearly present throughout the acute and delayed phases
thereafter. The precise transition between the acute and
delayed phases at 24 hours is arbitrary, however, and has no
clearly proven scientific basis; it is also of questionable
clinical relevance.24
In the present study, the most pronounced effect of
aprepitant was seen in the prevention of vomiting, with an
absolute difference of 17% between the aprepitant regimen
and the control group. Patients frequently cite vomiting as a
major concern of chemotherapy treatment, and hence, the
aprepitant benefit has important clinical significance. There
Table 3. Overall Summary of Clinical AEs and Neutrophil Counts
AE
% of Patients
Aprepitant Regimen
(n  438)
Control Regimen
(n  428)
Drug-related 21.5 19.6
Serious 3.4 4.2
Discontinuations due to AE 1.6 1.2
Febrile neutropenia 2.1 2.1
Abbreviation: AE, adverse events.
Those considered by the investigator to be possibly, probably, or
definitely related to study drug.
Fig 4. Bar graph showing percentage of
patients with an average score of  6 on a
7-point scale on the Functional Living Index–
Emesis questionnaire, signifying minimal or
no impact of emesis on daily living, for
total score overall and vomiting and nau-
sea domains. Black bars  aprepitant;
gray bars  control.
Fig 5. Time to first emesis. Kaplan-Meier curves for time-to-first emesis
from start of chemotherapy administration overall (0 to 120 hours) for cycle
1. Solid line  aprepitant regimen; dashed line  control regimen.
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was no significant effect of aprepitant on nausea, though it is
important to note again that the control group received active
therapywithondansetron forall 3days,whereas theaprepitant
group received ondansetron only on day 1. The more pro-
nounced effect of aprepitant and 5-HT3–receptor antagonists
on the prevention of vomiting compared with nausea implies
that serotonin and substance P may play a relatively more
important role in the pathogenesis of vomiting thanof nausea,
and that other neurotransmitters may also be involved in the
pathogenesis of these symptoms, especially nausea.
As seen in previous studies, the aprepitant regimenwas
well tolerated. Earlier studies assessing aprepitant use for
HEC13,14 showed a trend toward more fatigue with the
aprepitant regimen than with the control regimen; this was
not seen in the presentMEC study. The only notable differ-
ences between the treatment groups were a greater inci-
dence of constipation from the control regimen, a
predictable consequence of multiple-day 5-HT3–receptor
antagonist therapy, and more dyspepsia from the aprepi-
tant regimen. There was no evidence of any AEs caused by
potential interactions of aprepitant with chemotherapy
agents used in the current study; however, caution is ad-
vised when administering aprepitant to patients treated
with chemotherapy metabolized via CYP3A4.
In conclusion, the addition of aprepitant to an anti-
emetic regimen of ondansetron and dexamethasone re-
sulted in significantly better prevention of CINV than
ondansetron and dexamethasone alone in patients receiv-
ing moderately emetogenic chemotherapy. These and pre-
vious similar results for cisplatin-based highly emetogenic
chemotherapy demonstrate the utility of aprepitant as a
component of a regimen for the prevention of CINV across
a range of emetogenic chemotherapies. The data provide a
foundation for refinement of the aprepitant regimen, po-
tentially by increasing the duration of administration of the
concomitant 5-HT3–receptor antagonist and/or the corti-
costeroid to further improve the prevention of CINV asso-
ciated with MEC. Additional clinical trials are warranted.
■ ■ ■
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